Your session is about to expire
← Back to Search
Nivolumab for Neuroblastoma (MiniVan Trial)
MiniVan Trial Summary
This trialis researching a promising combination of drugs to improve outcome in neuroblastoma, a type of cancer in children. It will take place in 4 hospitals over 2 yrs, assessing safety & efficacy.
MiniVan Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533MiniVan Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You can participate in the study if you have a seizure disorder, but only if your seizures are under control with medication.You have symptoms of heart failure or an irregular heartbeat that is not under control.You have a serious neurological problem or severe peripheral neuropathy.You have noticeable fluid buildup around your lungs that is causing symptoms.You need or will likely need medications that weaken your immune system, like corticosteroids.You have neuroblastoma that has come back or has not responded well to previous treatment and is considered high risk according to the INRG criteria.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have there been any preceding investigations concerning Nivolumab?
"At present, 734 studies are being conducted regarding Nivolumab and 86 of them have reached Phase 3. Despite the focus on Zürich, BE for this study, there are an abundance of clinical trial locations around the world - 41224 in total."
Are there any available spots left for participants in this research?
"Affirmative. Information hosted on clinicaltrials.gov indicates that this medical research project is still accepting participants, with an initial posting date of May 24th 2018 and most recent update made October 26th 2022. The trial requires 36 patients to be recruited from one single site."
Who qualifies to enroll in the research program?
"Patients that are eligible for this experiment must have neuroblastoma and be between 1 year to 18 years in age. The recruitment goal is 36 participants."
To which maladies is Nivolumab typically deployed as a therapeutic agent?
"Nivolumab is commonly prescribed to combat malignant neoplasms, with additional efficacy in the treatment of conditions such as unresectable melanoma, metastatic esophageal adenocarcinoma and squamous cell carcinoma."
Is there an upper age limit for eligibility in this medical experiment?
"This medical trial is looking for participants between the ages of 1 and 18 years old."
What is the greatest amount of participants currently enrolled in this research endeavor?
"Affirmative. According to the data hosted on clinicaltrials.gov, this therapeutic trial is accepting new candidates as of October 26th 2022. It was initially posted May 24th 2018 and seeks 36 subjects at a single clinic site."
How reliable is Nivolumab when it comes to patient safety?
"As a Phase 1 trial, there is only minimal evidence of safety and efficacy for Nivolumab. Consequently, our team at Power have assigned it the lowest rating of 1 on its scale."
Share this study with friends
Copy Link
Messenger